NCT05447910View on ClinicalTrials.gov

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

TerminatedOBSERVATIONAL

Enrollment

21

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions

Breast AdenocarcinomaInvasive Breast CarcinomaResectable Breast Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood and tissue samples

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER